Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antidepressants in panic disorder.

A G Wade1

  • 1Community Pharmacology Services Ltd, Clydebank, UK.

International Clinical Psychopharmacology
|September 2, 1999
PubMed
Summary
This summary is machine-generated.

Selective serotonin reuptake inhibitors (SSRIs) like paroxetine and citalopram are now considered first-line treatments for panic disorder, showing superior efficacy over older antidepressants. Further research into combination therapies is needed for treatment-resistant cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of Influenza like Illness (ILI) in Children on Working Adults.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.

Psychological medicine·2011
Same author

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.

Journal of psychopharmacology (Oxford, England)·2010
Same author

Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).

Journal of psychiatric research·2008
Same author

Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.

The British journal of psychiatry : the journal of mental science·2001
Same author

Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·1999
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Panic disorder affects 1% of the population and frequently co-occurs with depression.
  • Established treatments include tricyclics, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and anticonvulsants.

Purpose of the Study:

  • To evaluate the efficacy of selective serotonin reuptake inhibitors (SSRIs) as first-line therapy for panic disorder.
  • To compare SSRIs with traditional treatments like tricyclic antidepressants.

Main Methods:

  • Review of studies on citalopram and paroxetine, focusing on efficacy and dosage.
  • Comparison of SSRI efficacy against comparator tricyclic antidepressants, such as clomipramine.

Main Results:

  • SSRIs, specifically citalopram (20-30 mg) and paroxetine, demonstrate significant efficacy for panic disorder.

Related Experiment Videos

  • SSRIs showed superior efficacy compared to clomipramine, a tricyclic antidepressant.
  • While effective, SSRIs and tricyclics have a delayed onset of action (up to 12 weeks) compared to benzodiazepines.

    • Conclusions:

    • Citalopram and paroxetine are recommended as first-line treatments for panic disorder due to their efficacy and tolerability.
    • Despite advances, a significant number of patients remain poorly controlled, highlighting the need for combination therapies in resistant panic disorder.